Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach

Journal of Clinical Pathology

Volumn 52, Issue 4, 1999, Pages 283-290

  Lagendijk, J H ^a   Mullink, H ^a   Van Diest, P J ^a   Meijer, G A ^a   Meijer, C J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast carcinoma; Colorectal carcinoma; Decision tree; Differential diagnosis; Discriminant analysis; Immunohistochemistry; Ovarian carcinoma

Indexed keywords

ANTIBODY; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; CYTOKERATIN 20; ESTROGEN RECEPTOR; VIMENTIN;

ARTICLE; BREAST ADENOCARCINOMA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; COLON ADENOCARCINOMA; COMPUTER ASSISTED DIAGNOSIS; DECISION THEORY; DIFFERENTIAL DIAGNOSIS; DISCRIMINANT ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY ADENOCARCINOMA; OVARY METASTASIS; PRIORITY JOURNAL;

EID: 0032960568     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.52.4.283     Document Type: Article

References (34)

1. 1 Rubin P, ed. Clinical oncology. A multidisciplinary approach, 6th ed. Rochester, NY: American Cancer Society, 1983.
2. 2 Wauters CCAP, Smeds F, Gerrits LGM, et al. Keratin 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol 1995;26:852-5.
3. 3 Ulbright TM, Roth LM, Stehman FB. Secondary ovarian neoplasia. A clinicopathologic study of 35 cases. Cancer 1984;53:1164-74.
4. 4 Webb MJ, Decker DG, Mussey E. Cancer metastatic tot the ovaries: factors influencing survival. Obstet Gynecol 1975; 45:396.
5. 5 Loy TS, Calaluce RD, Keeney GL. Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma. Mod Pathol 1996;11: 1040-4.
6. 6 Daya D, Nazerali L, Frank GL. Metastatic ovarian carcinoma of the large intestinal origin simulating primary ovarian carcinoma. A clinicopathologic study of 25 cases. Am J Clin Pathol 1992;97:751-8.
7. 7 Lash RH, Hart WR. Intestinal adenocarcinomas metastatic to the ovaries: a clinicopathologic evaluation of 22 cases. Am J Surg Pathol 1987;11:114-21.
8. 8 Monteagudo C, Merino MJ, PaPoerte N, et al. Value of gross cystic disease fluid protein-15 in distinguishing metastatic breast carcinomas among poorly differentiated neoplasms involving the ovary. Hum Pathol 1991;22:368-72.
9. 9 Gagnon Y, Tētu B. Ovarian metastases of breast carcinoma. A clinicopathological study of 59 cases. Cancer 1989;64: 892-8
10. 10 Young RH, Scully RE. Metastatic tumors of the ovary. In: Kurman RJ, ed. Blaustein's pathology of the female genital tract. New York: Springer-Verlag, 1994:939-74.
11. 11 Wick MR, Lillemoe TJ, Copland GT, et al. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol 1989;20: 281-7.
12. 12 Ramaekers F, Niekerk van C, Poels L, et al. Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas. Am J Pathol 1990;136:641-55.
13. 13 Guerrieri C, Franlund B, Boeryd B. Expression of cytokeratin 7 in simultaneous mucinous tumors of the ovary and appendix. Mod Pathol 1995:8:573-6.
14. 14 Ueda G, Sawada M, Ogawa H, et al. Immunohistochemical study of cytokeratin 7 for the differentiation of adenocarcinoma in the ovary. Gynecol Oncol 1993:51:219-23.
15. 15 Berezowski K, Stastny J, Kornstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol 1996;9:426-9.
16. 16 Moll R, Löwe A, Laufer J, et al. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 1992;140:427-47.
17. 17 Moll R, Pitz S, Levy R, et al. Complexity of expression of intermediate filament proteins, including glial filament protein, in endometrial and ovarian adenocarcinomas. Hum Pathol 1991;22:989-1001.
18. 18 Niekerk van CC, Ramaekers FCS, Hanselaar AGJM, et al. Changes in expression of differentiation markers between normal ovarian cells and derived tumors. Am J Pathol 1993;142:157-77.
19. 19 Viale G, Gambacorta M, Dell-Orto P, et al. Coexpression of cytokeratins and vimentin in common epithelial tumors of the ovary: an immunocytochemical study of eighty-three cases. Virchows Arch A Pathol Anat 1988;413:91-101.
20. 20 Nap M, Hammarstrom ML, Bormer O, et al. Specificity and affinity of monoclonal antibodies against carcinoembryonic antigen. Cancer Res 1992;52:2329-39.
21. 21 Pavelic ZP, Petrelli NJ, Herrera L, et al. D-14 monoclonal antibody to carcinoembryonic antigen; immunohistochemical analysis of formalin fixed, paraffin-embedded human colorectal carcinoma, tumors of non-colorectal origin and normal tissues. J Cancer Res Clin Oncol 1990;116: 51-6.
22. 22 Sheahan K, O'Brien MJ, Burke B, et al. Differential reactivities of carcinoembryonic antigen (CEA) and CEA-related monoclonal and polyclonal antibodies in common epithelial malignancies. Am J Clin Pathol 1990;94:157-64.
23. 23 Hensen-Logmans SC, Schipper NW, Poels LG, et al. Statistical evaluation of antigen profiles in the differential diagnosis between colonic and ovarian adenocarcinomas. J Clin Pathol 1988;41:644-9.
24. 24 Pavelic ZP, Pavelic L, Pavelic K, et al. Utility of anti carcinoembryonic antigen monoclonal antibodies for differentiating adenocarcinomas from gastrointestinal metastasis to the ovary. Gynecol Oncol 1991;40:112.
25. 25 Bast RC, Feeney M, Lazarus H, et al. Reactivity of an monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;8:1331-7.
26. 26 Loy TS, Quesenberry JT, Sharp SC. Distribution of CA 125 in adenocarcinomas. An immunohistochemical study of 481 cases. Am J Clin Pathol 1992;98:175-9.
27. 27 Kabawat SE, Bast RC, Welch WR, et al. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid and clear cell types. Am J Clin Pathol 1983;79:98-104.
28. 28 Mazoujian G, Bodian C, Haagensen DE, et al. Expression of GCDFP-15 in breast carcinomas. Cancer 1989;63:2156-61.
29. 29 Helin HJ, Helle MJ, Kallioniemi OP, et al. Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and DNA flow cytometry. Cancer 1989;63: 1761-7.
30. 30 Alberts SR, Ingle JN, Roche PR, et al. Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 1996;78:764-72.
31. 31 Takeda H, Yamakawa M, Takahashi T, et al. An immunohistochemical study with an estrogen receptor-related protein (ER-D5) in human colorectal cancer. Cancer 1992;69:907-12.
32. 32 Ollayos CW, Riordan P, Rushin JM. Estrogen receptor detection in paraffin sections of adenocarcinoma of the colon, pancreas, and lung. Arch Pathol Lab Med 1994;118: 630-2.
33. 33 Lagendijk JH, Mullink H, Diest van PJ, et al. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol 1998;29:491-7.
34. 34 McCarty KS, Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireccptor antibodies. Arch Pathol Lab Med 1985;109:716-21.